Evidence map›Paper›PMID 41675928›Full record

Observational studyFrontiers in cellular and infection microbiology2025

Real-world usage, effectiveness, and microbiological features of ceftazidime-avibactam in clinical practice in China.

Xiaohua Qin, Tianxin Xiang, Xiaoju Zhang, Xuzhu Ma, Weifeng Zhao, Yunsong Yu, Caiyan Zhao, Liang Gao, Lifen Li, Tiantian Wang and 11 more

Abstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Frontiers in cellular and infection microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Xiaohua QinInstitute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China.
Tianxin XiangDepartment of Infectious Diseases, The First Affiliated Hospital of Nanchang University, Nanchang, China.
Xiaoju ZhangDepartment of Pulmonary and Critical Care Medicine, Henan Provincial People's Hospital, Zhengzhou, China.
Xuzhu MaDepartment of Infectious Diseases, Beijing Tsinghua Changgung Hospital, Beijing, China.
Weifeng ZhaoDepartment of Infectious Diseases, The First Affiliated Hospital of Soochow University, Suzhou, China.
Yunsong YuDepartment of Liver Diseases and Infectious Diseases, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Caiyan ZhaoDepartment of Infectious Diseases, The Third Hospital of Hebei Medical University, Shijiazhuang, China.
Liang GaoDepartment of Neurosurgery, Shanghai Tenth People's Hospital, Shanghai, China.
Lifen LiDepartment of Critical Care Medicine, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Tiantian WangDepartment of Hematology, The Affiliated Hospital of Ningbo University Medical College, Ningbo, China.
Chongjie PangDepartment of Infectious Diseases, Tianjin Medical University General Hospital, Heping, China.
Xiaoyu ZhaoInstitute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China.
Renru HanInstitute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China.
Felix CaoChina Medical, Pfizer Inc, Beijing, China.
Ming SuChina Medical, Pfizer Inc, Shanghai, China.
Junchao LuChina Medical, Pfizer Inc, Shanghai, China.
Wenjuan XuChina Medical, Pfizer Inc, Beijing, China.
Shan YinChina Medical, Pfizer Inc, Shanghai, China.
Danni LuChina Medical, Pfizer Inc, Shanghai, China.
Xinyu YangChina Medical, Pfizer Inc, Beijing, China.
Minggui WangInstitute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Infections due to multidrug- and extensively drug-resistant bacteria can be difficult to treat and are associated with high mortality and burden of disease. Ceftazidime-avibactam (CVA) is used in patients with multidrug-resistant Gram-negative bacterial infections. Objective: To describe the real-world usage, effectiveness, and antimicrobial features of CVA in clinical practice in China. Methods: This multicenter, prospective observational study collected medical record data from adult patients (≥18 years) who had been hospitalized and treated with ≥1 dose of CVA. Clinical and microbiological outcomes were evaluated at the end of treatment, with clinical cure defined as resolution of infection following treatment with CVA. Results: Data were obtained from 220 adult patients receiving ≥1 dose of CVA in China. Infections indicated for CVA included pneumonia (64.5%), complicated intra-abdominal infection (16.8%) and bloodstream infection (7.3%). Conclusion: Findings from this study provide important real-world data on treatment patterns, microbiological features, and clinical and microbiological outcomes for CVA in routine clinical practice in China.

Indexed as

Anti-Bacterial AgentsAzabicyclo CompoundsCeftazidimeGram-Negative Bacterial InfectionsAdultAgedAged, 80 and overChinaDrug CombinationsDrug Resistance, Multiple, BacterialFemaleHumansMaleMicrobial Sensitivity TestsMiddle AgedProspective StudiesAnti-Bacterial Agentsavibactam, ceftazidime drug combinationAzabicyclo CompoundsCeftazidimeDrug CombinationsThird Generation Cephalosporinscarbapenem resistanceceftazidime-avibactamclinical outcomesmicrobiological outcomesreal-world evidence

Identifiers

PMID41675928
PMCPMC12886437

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.